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Reverse-phase protein array (RPPA) analysis is a powerful, rel-
atively new platform that allows for high-throughput, quantitative
analysis of protein networks. One of the challenges that currently
limit the potential of this technology is the lack of methods that al-
low for accurate data modeling and identification of related networks
and samples. Such models may improve the accuracy of biological
sample classification based on patterns of protein network activation
and provide insight into the distinct biological relationships underly-
ing different types of cancer. Motivated by RPPA data, we propose
a Bayesian sparse graphical modeling approach that uses selection
priors on the conditional relationships in the presence of class infor-
mation. The novelty of our Bayesian model lies in the ability to draw
information from the network data as well as from the associated
categorical outcome in a unified hierarchical model for classification.
In addition, our method allows for intuitive integration of a priori
network information directly in the model and allows for posterior
inference on the network topologies both within and between classes.
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Applying our methodology to an RPPA data set generated from pan-
els of human breast cancer and ovarian cancer cell lines, we demon-
strate that the model is able to distinguish the different cancer cell
types more accurately than several existing models and to identify
differential regulation of components of a critical signaling network
(the PI3K-AKT pathway) between these two types of cancer. This
approach represents a powerful new tool that can be used to improve
our understanding of protein networks in cancer.
1. Introduction.
1.1. Protein signaling pathways in cancer. The treatment of cancer is
rapidly evolving due to an improved understanding of the signaling pathways
that are activated in tumors. Global profiling of DNA mutations, chromo-
somal copy number changes, DNA methylations and gene expression have
greatly improved our appreciation of the heterogeneity of cancer [Nishizuka
et al. (2003), Blower et al. (2007), Gaur et al. (2007), Shankavaram et al.
(2007), Ehrich et al. (2008)]. However, the characterization of protein signal-
ing networks has proven to be much more challenging. Several reasons un-
derscore the critical importance of overcoming this challenge: first, changes
in cellular DNA and RNA both ultimately result in changes in protein ex-
pression and/or function, thus, protein networks represent the summation
of changes that happen at the DNA and RNA levels. Second, research has
demonstrated that many of the most common oncogenic genetic changes
activate proteins in kinase signaling pathways. Numerous studies of protein
networks and expression analysis have shown promising results. Due to the
hyperactivation of kinase signaling pathways, numerous kinase inhibitors
have been used in clinical trials, frequently with dramatic clinical activity.
Inhibitors that target protein signaling pathways have been approved by the
U.S. Food and Drug Administration for a variety of cancer types, including
chronic myelogenous leukemia, breast cancer, colon cancer, renal cell carci-
noma and gastrointestinal stromal tumors [as reviewed in Davies, Hennessy
and Mills (2006)].
Protein networks need to be assessed directly, as DNA or RNA analyses
often do not accurately reflect or predict the activation status of protein
networks. Many proteins are regulated by post-translational modifications,
such as phosphorylation or cleavage events, that are not detected by the
analysis of DNA or RNA. Several studies have also demonstrated marked
discordance between mRNA and protein expression levels, particularly for
genes in kinase signaling and cell cycle regulation pathways [Varambally
et al. (2005), Shankavaram et al. (2007)]. It has been demonstrated recently,
in both cancer cell lines and tumors, that different genetic mutations in the
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same signaling pathway can result in significant differences in the quantita-
tive activation levels of downstream pathway effectors [Stemke-Hale et al.
(2008), Davies et al. (2009), Vasudevan et al. (2009), Park et al. (2010)]. Al-
though these observations support the suggestion that direct measurements
are essential to measure protein network activation, a number of studies have
demonstrated that signaling pathways are frequently regulated by complex
feed-forward and feedback regulatory loops, as well as cross-talk between
different pathways [Mirzoeva et al. (2009), Zhang et al. (2009), Halaban
et al. (2010)]. Thus, developing an accurate understanding of the regula-
tion of protein signaling networks will be optimized by approaches that: (1)
assess multiple pathways simultaneously for different tumor types and/or
conditions, and (2) allow for the use of rigorous statistical approaches to
identify differential functional networks.
1.2. Reverse-phase protein lysate arrays. As explained, there is a strong
rationale for methods that will directly assess the activation status of protein
signaling networks in cancer. Traditional protein assays include immunohis-
tochemistry (IHC), Western blotting, enzyme-linked immunosorbent assay
(ELISA) and mass spectroscopy. Although IHC is a very powerful technique
for the detection of protein expression and location, it is critically limited
in network analyses by its non- to semi-quantitative nature. Western blot-
ting can also provide important information, but due to its requirement for
relatively large amounts of protein, it is difficult to use when comprehen-
sively assessing protein networks, and also is semi-quantitative in nature.
The ELISA method provides quantitative analysis, but is similarly limited
by requirements of relatively high amounts of specimen and by the high
cost of analyzing large pools of specimens. Mass spectroscopy is a pow-
erful, quantitative approach, but its utility is mainly limited by the cost
and time required to analyze individual samples, which limits the ability to
run large sample sets that are needed to appropriately assess characteristics
of disease heterogeneity and protein networks. Reverse-phase protein array
(RPPA) analysis is a relatively new technology that allows for quantitative,
high-throughput, time- and cost-efficient analysis of protein networks using
small amounts of biological material [Paweletz et al. (2001); Tibes et al.
(2006)].
RPPA data collection. We provide a brief overview of the RPPA exper-
iment and data collection. In order to perform RPPA, proteins are isolated
from the biological specimens such as cell lines, tumors or serum using stan-
dard laboratory-based methods. The protein concentrations are then de-
termined for the samples and, subsequently, serial 2-fold dilutions prepared
from each sample are then arrayed on a glass slide. Each slide is then probed
with an antibody that recognizes a specific protein epitope that reflects the
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Fig. 1. An example of a reverse-phase protein array (RPPA) slide. (A) Each slide is
comprised of 4 rows (A–D) of 12 columns (1–12) grids of 11X11 spots. (B) Each grid has
22 individual samples and 11 controls. Each row of the grid consists of 2 individual samples
(each with 5 serial 2-fold dilutions) and one control spot. Reproduced with permission from
Tabchy et al. (2011).
activation status of the protein. A visible signal is then generated through the
use of a signal amplification system and staining. The signal reflects the rel-
ative amount of that epitope in each spot on the slide, as shown in Figure 1.
The arrays are then scanned and the resulting images are analyzed with an
imaging software specifically designed for the quantification of RPPA analy-
sis (MicroVigene, VigeneTech Inc., Carlisle, MA). The relative signal inten-
sities of the dilution series for each sample on the array are used to calculate
the relative protein concentrations [Neeley et al. (2009), Zhang et al. (2009)].
Background correction is used to separate the signal from the noise by sub-
tracting the extracted background intensity from the foreground intensity
for each individual spot. Relative protein amount is calculated using a joint
estimation method that utilizes the logistic model of Tabus et al. (2006).
This method overcomes quenching at high levels and background noise at
low levels. An R package, SuperCurve, developed to use with this joint esti-
mation method is available at http://bioinformatics.mdanderson.org/
Software/OOMPA. As with most high-throughput technologies, the normal-
ization of the resulting intensities is conducted before any downstream anal-
ysis in order to adjust for sources of systematic variation not attributable to
biological variation. Technical differences in protein loading for each sample
are determined by first dividing the results for each protein measured by the
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average value among all the specimens, and then by determining the aver-
age value for each sample across all of the measured proteins. This relative
loading factor is then used to normalize the raw data for each sample, to
correct for any differences in protein loading between specimens. We refer
the reader to Paweletz et al. (2001) and Hennessy et al. (2010) for more
biological and technical details concerning RPPAs.
Biological researchers typically choose specific targeted pathways contain-
ing 50–200 proteins, usually assayed using the same number of arrays, with
each array hybridized against one protein. Because of the reverse design (as
compared to conventional gene expression microarrays), RPPAs allow much
larger sample sizes than the traditional microarrays, thus allowing detailed
and integrated analyses of protein signaling networks with higher statistical
power. Furthermore, this makes it possible to use RPPAs to measure protein
expression for multiple tumor classes and/or cell conditions. The scientific
aims we address using RPPA data in this paper are threefold: to infer differ-
ential networks between tumor classes/subtypes; to utilize a priori informa-
tion in inferring protein network topology within tumor classes/subtypes;
and, finally, to utilize network information in designing optimal classifiers
for tumor classification. We believe this will improve our understanding of
the regulation of protein signaling networks in cancer. Understanding the
differences in protein networks between various cancer types and subtypes
may allow for improved therapeutic strategies for each specific type of tu-
mor. Such information may also be relevant when determining the origin of
a tumor, which is clinically important in cases with indeterminate histologic
analysis, particularly for patients who have more than one type of cancer.
1.3. Graphical models for network analysis. A convenient and coherent
statistical representation of protein networks is accorded by graphical models
[Lauritzen (1996)]. By “protein network” we mean any graph with proteins
as nodes, where the edges between proteins may code for various biological
information. For example, an edge between two proteins may represent the
fact that their products interact physically (protein–protein interaction net-
work), the presence of an interaction such as a synthetic-lethal or suppressor
interaction [Kelley and Ideker (2005)], or the fact that these proteins code
for enzymes that catalyze successive chemical reactions in a pathway [Vert
and Kanehisa (2003)].
Our focus is on undirected graphical models and on Gaussian graphi-
cal models (GGM) in particular [Whittaker (1990)]. These models provide
representations of the conditional independence structure of the multivari-
ate distribution—to develop and infer protein networks. In such models, the
nodes represent the variables (proteins) and the edges represent pairwise de-
pendencies, with the edge set defining the global conditional independence
structure of the distribution. We develop an adaptive modeling approach
6 V. BALADANDAYUTHAPANI ET AL.
for the covariance structure of high-dimensional distributions with a focus
on sparse structures, which are particularly relevant in our setting in which
the number of variables/proteins (p) can exceed the number of observations
(n).
GGMs have been under intense methodological development over the past
few years in both frequentist [Meinshausen and Bu¨hlmann (2006), Chaud-
huri, Drton and Richardson (2007), Yuan and Lin (2007), Friedman, Hastie
and Tibshirani (2008), Bickel and Levina (2008)] and Bayesian settings [Giu-
dici and Green (1999), Roverato (2002), Carvalho and Scott (2009)]. Wong,
Carter and Kohn (2003) proposed a reversible jump MCMC-based Bayesian
model for covariance selection. In high-dimensional settings, Dobra et al.
(2004) used regression analysis to find directed acyclic graphs and converted
them to undirected (sparse) graphs to explore the underlying network struc-
ture, and Rodr´ıguez, Lenkoski and Dobra (2011) proposed a new approach
for sparse covariance estimation in heterogeneous samples. However, most
of the approaches we have cited focused on inferring the conditional inde-
pendence structure of the graph and did not consider classification, which
is one of the foci of our article. Rapaport et al. (2007) used spectral de-
composition to detect the underlying network structure and classify genetic
data using support vector machines (SVM). More recently, Monni and Li
(2010) proposed a graph-based regression approach incorporating pathway
information as a prior for classification procedures, however, their method
does not detect differential networks based on available data. Zhu, Shen
and Pan (2009) proposed network-based classification for microarray data
using support vector machines. This was extended to network-based sparse
Bayesian classifiers by Miguel Herna´ndez-Lobato, Herna´ndez-Lobato and
Sua´rez (2011), but these approaches do not estimate the network and also
do not take into account the differences in network structure between the
two classes. Another recent method is that of Fan, Jin and Yao (2013), who
propose a two-stage approach wherein they first select features and then
subsequently use the retained features and Fisher’s LDA for classification
using only one covariance matrix for both the classes.
In this article, we propose a constructive method for sparse graphical
models using selection priors on the conditional relationships in the pres-
ence of class information. Our method has several advantages over classical
approaches. First, we incorporate (integrate) the uncertainty of the param-
eters in deriving the optimal rule via Bayesian model mixing. Second, our
network model provides an adaptively regularized estimate of the covariance
matrix and hence is capable of handling n < p situations. More importantly,
our model uses this information in deriving the optimal classification bound-
ary. The novelty of our Bayesian model lies in the ability to draw information
from the network data from all the classes as well as from the associated cat-
egorical outcomes in a unified hierarchical model for classification. Through
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this process, it offers the advantages of sparse Bayesian modeling of GGM,
as well as the simplicity of a Bayesian classification model. In addition, with
available online databases containing tens of thousands of reactions and in-
teractions, there is a pressing need for methods integrating a priori pathway
knowledge in the proteomic data analysis models. We integrate prior infor-
mation directly in the model in an intuitive way such that the presence of an
edge can be specified by providing the probability of an edge being present
in the correlation matrix. Our method is fully Bayesian and allows for pos-
terior inference on the network topologies both within and between classes.
After fitting the Bayesian model, we obtain the posterior probabilities of
the edge inclusion, which leads to false discovery rate (FDR)-based calls on
significant edges.
The structure of our paper is as follows. In Section 2 we outline our
Bayesian graph-based model for classification of RPPA data. Section 3 fo-
cuses on Bayesian FDR-based determination of significant networks. Sec-
tion 4 presents the results of our case study using an RPPA experiment.
We end with a discussion and conclusion in Section 5. All technical details
and additional analysis results are presented in the supplementary material
[Baladandayuthapani et al. (2014)].
2. Probability model. Our data construct for modeling is as follows.
We observe a tuple: (Zi,Yi), i = 1, . . . , n, where Zi is a categorical out-
come denoting the type or subtype of cancer (binary or multi category)
and Yi = (Y
(1)
i , . . . , Y
(p)
i ) is a p-dimensional vector of proteins assayed for
the ith sample/patient/array. We detail the model here for binary classifica-
tion (when Zi is a binary variable), noting that generalization to multi-class
classification can be achieved in an analogous manner. We factorize the joint
distribution (likelihood) of the data p(Yi,Zi), ∀i in the following manner
p(Yi,Zi) = p(Yi|Zi)p(Zi),
where the first component models the joint distribution of the p proteins
given the class variable Zi and the second component models the marginal
distribution of the class variables. We model the first component as a mixture
of the multivariate normal distributions as
p(Yi|Zi,µ,Ω)∼ ZiN(µ
(1),Σ(1)) + (1−Zi)N(µ
(2),Σ(2)),
where µ(•) andΣ(•) are the corresponding means and covariances for the two
classes. To specify the marginal component, we note that in the classification
framework only a fraction of Z’s, say Zu, will be unobserved (specifically
in the case of prediction, as shown in Section 2.2) and they will be further
modeled as
p(Zu|h)∼Bernoulli(h),
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where we assign a Beta prior on probability h as h∼ Beta(η, ζ). Note that
this prior can be generalized to be class-specific by allowing h to depend on
the class k by changing the corresponding hyperparameters ηk, ζk.
Our main constructs of interest in this framework are (µ(k),Σ(k)), k = 1,2
for each of the classes, where the latter provides a dependence structure be-
tween the proteins, which we model in a GGM framework. The key idea
behind GGMs is rather to model the precision matrix Ω(k) =Σ(k)
−1
, which
dictates the network structure between the variables. In this framework
of particular interest is the identification of zero entries in the precision
matrix—a zero entry at the ijth element of Ω indicates conditional inde-
pendence between the two random variables Yi and Yj , given all other
variables. This is often referred to as the covariance selection problem in
GGMs [Dempster (1972), Cox and Wermuth (2002)]. In the section below
we provide a constructive method for sparse estimation (identification of
many zeros) of the precision matrix in high-dimensional settings, but also
allow for borrowing strength between classes to estimate the class-specific
precision matrices for conducting classification.
2.1. Parameterization of the precision matrix. Given the number of vari-
ables p, the size of the precision matrix (p× p) is potentially of high dimen-
sion. Instead of specifying a global (joint) distribution on the precision ma-
trix, we explore local dependencies by breaking it down into components. For
some applications, it is desirable to work directly with standard deviations
and correlations [Barnard, McCulloch and Meng (2000), Liechty, Liechty
and Mu¨ller (2004)] that do not correspond to any type of parameteriza-
tion (e.g., Cholesky, etc.). This parameterization has a practical motivation
because most biologists think in terms of correlations between the proteins,
thus easing prior elicitation, as we show below. To this end, we parameterize
the precision matrix (for each class k, suppressing the superscript for ease
of notation) as Ω= S×C× S, where S is a diagonal matrix with nonzero
diagonal elements that contains the inverse of the partial standard devia-
tions and C is a matrix that contains partial correlation coefficients. Note
that the correlation matrix C satisfies the properties of a correlation matrix,
that is, the partial correlation coefficients (ρij) between variables i, j share
a one-to-one correspondence to the elements Cij as
ρij =
−Ωij
(ΩiiΩjj)1/2
=−Cij.
Due to this correspondence, sparse estimation of Ω directly implies the
identification of zeros in the elements of C. Thus, we model C as a convo-
lution,
C=A⊙R,
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where ⊙ is the Hadamaard operator indicating element-wise multiplication
between the two (stochastic) matrices: a selection matrix A and the corre-
sponding correlation matrix R with the following properties:
• Both A and R are symmetric.
• Both A and R have ones as their diagonal elements.
• The off-diagonal elements of A are either 0 or 1 and the off-diagonal
elements of R lie in the range [−1,1].
• Both A and R need not be positive definite, but the convolution C has
to be positive definite.
In essence, A is a binary selection matrix that selects which of the ele-
ments in R are zero or nonzero. In other words, A performs variable selec-
tion on the elements of the matrix R by shrinking the nonrequired variables
(edges) exactly to zero and thus inducing sparsity in the estimation of the
resulting precision matrix governing the GGM. We discuss hereafter the
estimation and prior specifications for each of these matrices.
Prior construction. R is a matrix with all of its off-diagonal elements
in the range [−1,1], therefore, we assign an independent uniform prior over
[−1,1] for all Rij , i < j. Correspondingly, since the off-diagonal elements
of A are binary (0 or 1), we assign an independent Bernoulli prior with
probability qij for the element Aij , i < j. Note that this element-wise prior
specification on A and R does not ensure that the C (=A⊙R) is positive
definite—hence a valid graph. Thus, a key ingredient of our modeling scheme
is that we need an additional constraint: C ∈ Cp where Cp is the space of
all proper correlation matrices of dimension p, such that the joint convolved
prior on A and R can be written as
A,R|q∼
∏
i<j
{UniformRij [−1,1]BernoulliAij (qij)}I(A⊙R ∈Cp),
where I(•), the indicator function, ensures that the correlation matrix is
positive definite and introduces dependence among the elements of the ma-
trices R,A, and qij is the probability of the ijth element being selected as
1.
We ensure the positive-definiteness constraint in our posterior sampling
schemes. Specifically, we perform MCMC sampling in such a way that the
constraint C ∈Cp is satisfied—to search over the possible space of valid cor-
relation matrices. To implement the constraint, we draw Rij ,Aij , sequen-
tially conditioned on all other elements of R and A such that the realized
value of Cij ensures C is positive definite given all other parameter values.
Briefly, we follow the method of Barnard, McCulloch and Meng (2000) to
find the range [uij , vij] on the individual elements of R that will guarantee
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the positive definiteness of C. The resulting form of the conditional prior on
the off-diagonal elements Rij can be written as
Rij|aij ,A−ij ,R−ij ∼Uniform(uij , vij)I(−1<Rij < 1), i 6= j, i < j,
where R−ij contains all other off-diagonal elements of R except the ijth
element and A−ij contains all elements of A except the ijth element. The
limits of the Uniform distribution uij and vij are chosen such thatC=A⊙R
is positive definite and (conditionally) uij and vij are functions of R−ij and
A−ij (see Appendix A in the supplementary material [Baladandayuthapani
et al. (2014)] for the detailed proof).
In this construction, the parameter probability qij controls the degree of
sparsity in the GGM in an adaptive manner by element-wise selection of
the entries of the correlation matrix. We assign a beta hyperprior for the
probabilities qij as
qij ∼Beta(aij , bij), i 6= j,
where the hyperparameters aij , bij can be set to induce prior information
on the graph structure (see Section 2.3). To complete the hierarchical spec-
ification, we choose an (exchangeable) inverse-gamma prior on the inverse
of the partial standard deviations S, which is a diagonal matrix containing
entries Si =Ω
1/2
ii as Si ∼ IG(g,h), i= 1,2, . . . , p.
Borrowing strength between classes. Note that in the above construc-
tion all the parameters are class-specific, that is, are different for each class
k, and thus model fitting and estimation can be done for each class sepa-
rately. But the main advantage of Bayesian methodology lies in borrowing
strength between the classes for both estimation of the graphical structure
and subsequent prediction/classification. This can be accomplished by hav-
ing a variable that introduces dependence between the classes linking the
selection matrix A. We introduce a latent variable λij defined as
λij =
{
1, if A1ij 6=A
2
ij ,
0, if A1ij =A
2
ij ,
where A1 and A2 are the class-specific selection matrices. The binary vari-
ables λij ’s imply the presence or absence of the same edge in the graphical
model of both classes. In other words, λij = 1 signifies a differential edge
(i.e., the relation between the covariates i, j is significant in only one class
but not the other), whereas λij = 0 signifies a conserved edge (i.e., the rela-
tion between the covariates i, j is significant in both classes). Thus, the λ’s
serve a dual purpose in our model setup. They not only introduce depen-
dence between the classes, since they are shared between both classes, but
also have a distinct interpretation in terms of differential/conserved patterns
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of dependence between the graphs for the classes. This information is vital
for understanding the biological processes and inferring conclusions from the
analysis, as we show in Section 4.
Since the λij ’s are binary random variables, we propose a Bernoulli prior
on λij as
λij ∼ Bernoulli(piij), i < j,
where the parameter piij is the probability that the relation between the ith
and jth variables is different. We further assign a beta hyperprior for the
probabilities piij as
piij ∼ Beta(eij , fij), i 6= j.
To complete the prior specification on the graphical model, we propose a
normal prior on the means (µ(1),µ(2)) as
µ(k) ∼N(µ
(k)
0 ,B
−1
0
(k)
), k = 1,2.
2.2. Prediction. In this section we lay out our graph-based prediction
(classification) scheme. Suppose the class variables Z (of size n × 1) are
partitioned into a vector of training samples Zt (of size nt× 1) and a vector
of (unknown) test/validation cases Zu (of size nu× 1) to be predicted. The
corresponding observed variables are also partitioned as [Yt;Yu]. Denote the
observed data by D = {Yt,Zt,Yu}. In Bayesian prediction, for a new sample
with protein expression information Yu, we have to obtain the posterior
predictive probability that its class variable Zu, given all observed data D,
is p(Zu|D).
To estimate these probabilities, we treat Zu ≡ {Zuo :o = 1, . . . , nu} as a
parameter in the model and extend the MCMC analysis to sample these
values at each iteration. Specifically, we draw Zu from the corresponding
conditional posterior distribution in each MCMC iteration (see Appendix
B in the supplementary material [Baladandayuthapani et al. (2014)] for the
full conditional distribution). The way our model is specified, the posterior
distribution of Zu is analyzed conditional not only on all the data from both
classes D, but also on the parameters that are shared between the classes.
Thus, the predictions are obtained in a single MCMC fitting procedure along
with all other parameters, thereby accounting for all sources of variation. We
note that the limitation of this method is that training and test splits of the
data must be contemplated prior to analysis (as is usually done) and/or
analysis fully repeated if new predictions are required.
The complete hierarchical formulation of our graph-based binary classifi-
cation model can be succinctly summarized as shown hereafter. In addition,
the directed acyclic graph (Figure 6 in the supplementary material [Baladan-
dayuthapani et al. (2014)]) shows a graphical representation of our model
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where the circles indicate parameters and the squares observed random vari-
ables:
Y = [Yt,Yu]∼ZN(µ(1),Ω−1
(1)
) + (1−Z)N(µ(2),Ω−1
(2)
),
Z= [Zt,Zu],
Zuo ∼ Bernoulli(ho),
ho ∼ Beta(η, ζ),
µ(k) ∼N(µ
(k)
0 ,B
−1
0
(k)
),
Ω(k) = S(k)(A(k) ⊙R(k))S(k),
A(k),λ,R(k)|q(k),pi ∼
∏
i<j
Uniform(uij , vij)Bernoulli(q
(k)
ij )
×Bernoulli(piij)I(C
(k) ∈Cp),
q
(k)
ij ∼ Beta(α
(k)
ij , β
(k)
ij ),
piij ∼ Beta(eij , fij), i 6= j,
S
(k)
i ∼ IG(g,h),
where k = 1,2 corresponds to the two classes, i, j = 1, . . . , p, and o= 1, . . . , nu
corresponds to the size of the test/validation sample. The full conditional
distributions for MCMC sampling of the model parameters and random
variables are provided in Appendix B in the supplementary material [Bal-
adandayuthapani et al. (2014)].
2.3. Incorporating prior pathway information and hyperparameter set-
tings. As we mentioned before, there exists a huge amount of literature
(prior knowledge) describing the functional behaviors of proteins, as charac-
terized in metabolic, signaling and other regulation pathways. We formally
incorporate this a priori knowledge in our model through the hyperparam-
eter settings on the prior specification of qij , the probability that the edge
between protein (i, j) will be selected. In particular, we impose an informa-
tive prior on pi(qij)∼ Beta(aij , bij) and set the hyperparameters aij and bij
such that the distribution has a higher mean to reflect our prior knowledge
of the presence of an edge. For example, one could set the following:
• prior on qij as Beta(2,10) with mean 0.17, if there is biological evidence
that the edge does not play an important role in the pathway;
• prior on qij as Beta(10,2) with mean 0.83, if there is biological evidence
that the edge plays an important role in the pathway;
• prior on qij as Beta(2,2) with mean 0.5, if no prior information is available.
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The prior information incorporated in the qij ’s from online databases is as-
sumed to represent normal conditions only. Information on relations between
proteins that is affected by an intervention and/or mutation can be elicited
by expert opinion (e.g., from a biologist). Information on the edges of graphs
that is perturbed by a mutation can be incorporated formally through our
prior on piij , the probability that controls the differential/conserved edge
between two different conditions. We specify informative priors in a manner
analogous to that of qij (as shown above) in cases where such information
exists by setting eij , fij similarly to aij and bij . Finally, for the hyperparam-
eters of the variance components, we obtain a vague inverse gamma prior
by setting (g,h) = 1 and set the hyperparameters for the beta prior on ho
to be diffuse using (η, ζ) = 2.
3. FDR-based determination of significant networks. Once we apply the
MCMC methods, we are left with posterior samples of the model parameters
that we can use to perform Bayesian inference. Our objective is twofold: to
detect the “best” network/pathway based on the significance of the edges
and also to detect differential networks between treatment classes. Given p
proteins, our network consists of p(p− 1)/2 unique edges, which could be
large even for a moderate number of proteins. Therefore, we need a mecha-
nism that will control for these large-scale comparisons, discover edges that
are significant and also detect differential edges between classes. We ac-
complish this in a statistically coherent manner using false discovery rate
(FDR)-based thresholding to find significant networks and also to differen-
tiate networks across samples.
The MCMC samples explore the distribution of possible network configu-
rations suggested by the data, with each configuration leading to a different
topology of the network based on the model parameters. Some edges that are
strongly supported by the data may appear in most of the MCMC samples,
whereas others with less evidence may appear less often. There are differ-
ent ways to summarize this information in the samples. One could choose
the most likely (posterior mode) network configuration and conduct con-
ditional inference on this particular network topology. The benefit of this
approach would be the yielding of a single set of defined edges, but the draw-
back is that the most likely configuration may still appear only in a very
small proportion of MCMC samples. Alternatively, one could use all of the
MCMC samples and, applying Bayesian model averaging (BMA) [Hoeting
et al. (1999)], mix the inference over the various configurations visited by
the sampler. This approach better accounts for the uncertainty in the data,
leads to estimators of the precision matrix with the smallest mean squared
error and should lead to better predictive performance in class predictions
[Raftery, Madigan and Hoeting (1997)]. We will use this Bayesian model
averaging approach.
14 V. BALADANDAYUTHAPANI ET AL.
From our MCMC iterations, suppose we have M posterior samples of the
corresponding parameter set {A
(m)
ij ,m= 1, . . . ,M}, for which the selection
indicator of the ijth edge is in the model. Suppose further that the model
averaged set of posterior probabilities is set P , the ijth element of which
Pij =M
−1
∑
mA
(m)
ij and is a p × p-dimensional matrix. Note that 1− Pij
can be considered Bayesian q-values, or estimates of the local false discovery
rate [Storey and Tibshirani (2003), Newton et al. (2004)], as they measure
the probability of a false positive if the ijth edge is called a “discovery” or is
significant. Given a desired global FDR bound α ∈ (0,1), we can determine
a threshold φα with which to flag a set of edges Xφ = {(i, j) :Pij ≥ φα} as
significant edges.
The significance threshold φα can be determined based on classical Bayesian
utility considerations such as those described in Mu¨ller et al. (2004) and
based on the elicited relative costs of false-positive and false-negative er-
rors or can be set to control the average Bayesian FDR, as in Morris et al.
(2008). The latter is the process we follow here. For example, suppose we
are interested in finding the value φα that controls the overall average FDR
at some level α, meaning that we expect that only 100α% of the edges
that are declared significant are in fact false positives. Let vec(P) = [Pt; t=
1, . . . , p(p−1)/2] be the vectorized version of the set P containing the unique
posterior probabilities of the edges, stacked columnwise. We first sort Pt in
descending order to yield P(t), t= 1, . . . , p(p− 1)/2. Then φα = P(ξ), where
ξ =max{j∗ : j∗−1
∑j∗
j=1P(t) ≤ α}. The set of regions Xφα then can be claimed
to be significant edges based on an average Bayesian FDR of α.
This FDR-based thresholding procedure can be extended to find differen-
tial networks between different populations (tumor classes/subtypes), for ex-
ample, to identify edges that are significantly different between tumor types.
To this end, we use the corresponding parameter set {λ
(m)
ij ,m= 1, . . . ,M},
which is the selection indicator of the differential edge between the ijth co-
variates in the model. The model averaged set of posterior probabilities is set
Pd, the ijth element of which Pdij =M
−1
∑
m λ
(m)
ij . We use this same pro-
cedure to arrive at a set of differential edges Xφ = {(i, j) :P
d
ij ≥ φα} with φα
chosen to control the Bayesian FDR at level α. We use a similar procedure
on the parameter set {1−λ
(m)
ij ,m= 1, . . . ,M}, to arrive at a set of common
edges Xφ = {(i, j) :P
c
ij ≥ φα} with φα chosen to control the Bayesian FDR
at level α.
4. Data analysis.
4.1. Classification of breast and ovarian cancer cell lines. Breast and
ovarian cancer are two of the leading causes of cancer-related deaths in
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women [Jemal et al. (2009)]. Both of these diseases are frequently affected
by mutations in kinase signaling cascades, particularly those involving com-
ponents of the PI3K-AKT pathway [Mills et al. (2003), Hennessy et al.
(2008), Yuan and Cantley (2008), Bast Jr., Hennessy and Mills (2009)].
The PI3K-AKT pathway is one of the most important signaling networks
in carcinogenesis [Vivanco and Sawyers (2002)] and is affected more than
any other signaling pathway by activating mutations in cancer tissues [Yuan
and Cantley (2008)]. Aggressive drug development efforts have targeted this
critical oncogenic pathway, and inhibitors of multiple different components
of the PI3K-AKT pathway have been developed and are in various stages of
preclinical and clinical testing [Hennessy et al. (2005), Courtney, Corcoran
and Engelman (2010)].
We applied our methodology to identify differences in the regulation of
the PI3K-AKT signaling network in breast and ovarian cancers. For this
analysis, we used expression data of p = 50 protein markers in signaling
pathways from an RPPA analysis of human breast (n1 = 51) and ovarian
(n2 = 31) cancer cell lines grown under normal tissue culture conditions
[Stemke-Hale et al. (2008)]. We used the known connections in the PI3K-
AKT pathway suggested by previous studies and expert opinion as a priori
information in our model, as stated in Section 2.3.
The significant networks based on a Bayesian FDR cutoff of α= 0.1 for
breast and ovarian cancer samples are shown in Figure 2(a) and (b), re-
spectively. The red edges indicate a negative association (regulation) and
the green edges indicate a positive interaction between the proteins. The
edges are represented by lines of varying degrees of thickness based on the
strength of the association (correlation), with higher weights having thicker
edges and lower weights having thinner edges. In order to identify biological
similarities and differences between the breast and ovarian cancer cell lines,
we compared the results of our network analyses of the two cancer types.
Plotted in Figure 3(a) are the conserved (common) edges between the two
cancer types. The differential network between the two cancer types, con-
trolling for a Bayesian FDR cutoff of α= 0.1, is shown in Figure 3(b).
A number of protein–protein relationships demonstrated significant sim-
ilarity between the two cancer types. For example, both breast cancer and
ovarian cancer cell lines exhibited a marked negative association between
the levels of PTEN and phosphorylated AKT (Akt.pT308). This relation-
ship was expected due to the critical regulation of 3-phopshatidylinositols
by the lipid phosphatase activity of PTEN, and has previously been demon-
strated as a significant interaction in multiple tumor types [Davies et al.
(1998, 1999, 2009), Stemke-Hale et al. (2008), Vasudevan et al. (2009),
Park et al. (2010)]. Although this concordance was expected, our analy-
sis also identified a large network of differential protein interactions among
the breast and ovarian cancer cell lines [Figure 3(b)]. In this figure, the
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(a) Breast network
(b) Ovary network
Fig. 2. Significant edges for the proteins in the PI3K-AKT kinase pathway for breast (a) and ovarian cancer cell lines (b) computed
using a Bayesian FDR of 0.10. The red (green) lines between the proteins indicate a negative (positive) correlation between the proteins.
The thickness of the edges corresponds to the strength of the associations, with stronger associations having greater thickness.
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(a) Conserved network between ovarian and breast cancer cell lines
(b) Differential network between ovarian and breast cancer cell lines
Fig. 3. Conserved and differential networks for the proteins in the PI3K-AKT kinase
pathway between breast and ovarian cancer cell lines computed using a Bayesian FDR set
to 0.10. In the conserved network (top panel), the red (green) lines between the proteins
indicate a negative (positive) correlation between the proteins. In the differential network
(bottom row), the blue lines between the proteins indicate a relationship that was significant
in the ovarian cancer cell lines but not in the breast cancer cell lines; the orange lines
between the proteins indicate a relationship in the breast cancer cell lines but not in the
ovarian cancer cell lines. The thickness of the edges corresponds to the strength of the
associations, with stronger associations having greater thickness.
edges in blue indicate relationships between proteins that were present in
the ovarian cancer cell lines but not in the breast cancer cell lines using
our FDR cutoff, and the orange edges indicate relationships present in the
breast cancer cell lines but not in the ovarian cancer cell lines. In addi-
tion, the thickness of the edges corresponds to the strength of the associa-
tion. Notable differential connections in this analysis include the association
of phosphorylated AKT (Akt.pS473) with BCL-2 (Bcl2) and phosphory-
lated MAPK (MAPK.pT202.Y204) in breast cancer. Both of these, BCL-
2(Bcl2) and phosphorylated (activated) MAPK (MAPK.pT202.Y204), may
contribute to tumor proliferation and survival, and are therapeutic targets
with available inhibitors. The association of different proteins with the ex-
pression of the estrogen receptor, phosphorylated PDK1 (PDK1.pS241) and
MAPK (MAPK.pT202.Y204) in breast cancer and phosphorylated AMPK
(AMPK.pT172) in ovarian cancer, may also have therapeutic implications,
as the estrogen-receptor blockade is a treatment used in both advanced
breast and ovarian cancer.
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Table 1
Misclassification error rates for different classifiers for ovarian and breast cancer data
sets. The methods compared here are SVM (network-based support vector machine), LDA
(linear discriminant analysis), KNN (K-nearest neighbor), DQDA (diagonal quadratic
discriminant analysis), DLDA (diagonal linear discriminant analysis), NBC (naive
Bayes classifier) and BGBC (Bayesian graph-based classifier), which is the method
proposed in this paper with and without incorporating prior information, denoted by
BGBC (prior) and BGBC (w/o prior), respectively. The mean and the standard
deviation are values of the misclassification percentage over 100 random splits of the data
SVM KNN LDA DLDA DQDA NBC BGBC BGBC w/o prior
Mean 8.03 15.14 25.48 12.07 13.74 13.37 6.59 10.88
SD 5.44 6.82 10.63 5.829 6.70 6.96 4.06 6.31
We used this network information to build a classifier to distinguish be-
tween breast cancer and ovarian cancer samples as explained in Section 2.
We assessed the performance of the classifiers using cross-validation tech-
niques. In particular, we generated 100 random selections of training and
test data sets with 66% and 33% splits of the data, respectively. We fit
our Bayesian graph-based classifier (BGBC) and compared our method to
six other methods: the network-based support vector machine (SVM) [Zhu,
Shen and Pan (2009)],K-nearest neighbor (KNN), linear discriminant analy-
sis (LDA), diagonal linear discriminant analysis (DLDA), diagonal quadratic
discriminant analysis (DQDA) and naive Bayes classifier (NBC) [John and
Langley (1995)] methods. We implemented the network-based SVM using
the R package “pathclass.” The network structure was specified to be the
common network for the two classes obtained from the BGBC algorithm, as
this method does not explicitly estimate the network. All other input param-
eters were set at the default settings for the network-based SVM function.
We implemented all the other methods using the corresponding MATLAB
functions.
The average misclassification errors (along with standard errors) across
all splits for all the methods on the test set are shown in Table 1. The
BGBC method had much lower misclassification rates compared to the other
methods (the other methods ignore the underlying network structure of the
proteins). We believe that this improved precision is due to the fact that
the mean expression profiles of the breast and ovarian cancer cell lines are
very similar so there is not enough information in the mean to classify the
two cases. Hence, means-based classifiers, especially KNN and LDA (both of
which use identity and diagonal covariances), underperform as compared to
our method. The results of the DQDA method could be a bit closer to those
of the BGBC method, but the former method ignores the cross-connections,
that is, network information, and hence results in a higher misclassification
BAYESIAN SPARSE GRAPHICAL MODELS 19
rate. The QDA could not be performed because the estimation of different
covariance matrices for different classes is an ill-posed problem for n< p. We
also tested the performance of BGBC using prior information and without
using prior information in estimating the networks. The last two columns
of Table 1 show that incorporating prior information improves our classi-
fication performance. Furthermore, the inclusion of prior information leads
to sparser networks (as shown in Figure 7 in the supplementary material
[Baladandayuthapani et al. (2014)]), as the prior information provides in-
formation about important and unimportant relationships, which aids our
classification model.
We further note that nonlinear (quadratic) boundaries are obtained by
using network information (since we model the covariance matrix), whereas
linear boundaries are obtained by ignoring the network information (lin-
ear/diagonal discriminant based approaches). The classification boundary
(Figure 8 in the supplementary material [Baladandayuthapani et al. (2014)])
exemplifies our intuition and approach. We have a p(= 50)-dimensional
quadratic classification boundary based on the GGM. In order to visualize
this, we projected the boundary and the data onto two randomly selected
dimensions/covariates. Two of those projections are shown in the figure,
which confirm our intuition of how nonlinear boundary is more effective
than a linear boundary in classification.
4.2. Effects of tissue culture conditions on network topology. Cell lines
derived from tumors are a powerful research tool, as they allow for detailed
characterization and functional testing. Genetic studies support the concept
that cell lines generally mirror the changes that are detected in tumors,
particularly at the DNA and RNA levels [Neve et al. (2006)]. However,
the activation status of proteins can be impacted by the use of different
environmental conditions in the culturing of cells. A key scientific question
in the analysis of protein networks in cancer cell lines is the variability of
network topologies due to differing tissue culture conditions. In order to
assess if different network connectivity is observed under varying culture
conditions, we used three different tissue culture conditions to grow the 31
ovarian cancer cell lines used in the previous analysis.
For condition “A,” the cells were grown in tissue culture media that was
supplemented with growth factors in the form of fetal calf serum (5% of
the total volume), which is a standard condition for the culturing of cancer
cells. For condition “B,” the cells were harvested after being cultured in
the absence of growth factors (serum) for 24 hours. For condition “C,” cells
were grown in the absence of growth factors for 24 hours, then they were
stimulated acutely (20 minutes) with growth factors (5% fetal calf serum).
Proteins were harvested from each cell line for each tissue culture condi-
tion. The experimental procedure used for the isolation and RPPA analysis
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of proteins from the cancer cells growing under normal, serum-replete tis-
sue culture conditions has been described previously [Davies et al. (2009),
Park et al. (2010)]. Protein isolation, processing and RPPA analysis were
performed using the same methodology for all three conditions.
The RPPA data for each condition were then analyzed for protein–protein
interactions using the GGM method. The topology maps for the ovarian
cancer cells for the A, B and C tissue culture conditions are shown in Fig-
ure 12(a), (b) and (c) (provided in the supplementary material [Baladan-
dayuthapani et al. (2014)]), respectively. We then performed comparisons of
the results based on each of the three conditions in order to identify protein
topology networks that were similar and different between each of the tis-
sue culture conditions. As conditions A (media replete with growth factor)
and B (media starved of growth factor) both represented steady-state tis-
sue culture conditions, we initially compared these protein networks using
a Bayesian FDR of 10%. The networks that are shared between the two
conditions are shown in Figure 4(a); the differential associations are pre-
sented in Figure 4(d). We detected 21 significant protein interactions that
were common for conditions A and B, and 4 interactions that were different.
Thus, the overwhelming majority of protein–protein associations that were
observed were maintained regardless of the presence or absence of growth
factors (serum) in the tissue culture media. We then compared the significant
relationships identified for condition B (media starved of growth factor) ver-
sus condition C (media starved, then acutely stimulated with growth factor).
This comparison showed increased discordance of results, as we detected 20
associations that were common for conditions B and C [Figure 4(b)], but 11
associations that differed significantly [Figure 4(e)]. Similarly, the compari-
son of networks between the A and C conditions identified 22 shared protein
interactions [Figure 4(c)] and 12 differential interactions [Figure 4(f)]. Of the
differential interactions noted for the comparisons of conditions B versus C
and A versus C, only 2 were observed in both comparisons (c-KIT and P38;
VEGFR2 and MAPK.pT202.Y204). Neither of these 2 relationships was
among the differential protein interactions in the analysis of condition A
versus condition B. Of the 4 relationships that differed in the comparison
of condition A versus condition B, 3 of the relationships were also identified
as differing significantly when comparing condition B versus condition C
(eIF4E and P38.pT180.Y182; c-Kit and PARP.cleaved; PARP.cleaved and
ER.alpha), and the fourth differed significantly for the comparison of condi-
tion A versus condition C (AMPK.pT172 and eIF4E). This analysis suggests
that protein–protein relationships are largely maintained under steady-state
tissue culture conditions. However, these interactions may differ significantly
in the setting of acute growth factor stimulation. We have included the ex-
plicit comparisons of our inferred networks with the prior PI3K-AKT path-
way in Figures 13–16 in the supplementary material [Baladandayuthapani et
BAYESIAN SPARSE GRAPHICAL MODELS 21
(a) Conserved network of Ovary A and Ovary B
(b) Conserved network of Ovary B and Ovary C
(c) Conserved network of Ovary A and Ovary C
(d) Differential network (e) Differential network (f) Differential network
of Ovary A and Ovary B of Ovary B and Ovary C of Ovary A and Ovary C
Fig. 4. Conserved and differential networks for the proteins in the PI3K-AKT kinase
pathway between ovarian cancer cell lines grown in three different tissue culture condi-
tions: A, B and C (see main text) computed using a Bayesian FDR set to 0.10. In the
conserved network [ (a)–(c)], the red (green) lines between the proteins indicate a negative
(positive) correlation between the proteins. In the differential network [ (d)–(f)], the blue
lines between the proteins indicate a relationship that was significant in the ovarian cancer
cell lines but not in the breast cancer cell lines; the orange lines between the proteins indi-
cate a relationship in the breast cancer cell lines but not in the ovarian cancer cell lines.
The thickness of the edges corresponds to the strength of the associations, with stronger
associations having greater thickness.
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al. (2014)]. The posterior means of the covariance matrices corresponding to
the networks are also now plotted as heat maps in Figures 17–20 in the sup-
plementary material [Baladandayuthapani et al. (2014)]. The exact posterior
mean estimates are also provided as excel files downloadable from the cor-
responding authors’ website at http://odin.mdacc.tmc.edu/~vbaladan/
Veera_Home_Page/Software_files/Covariance_Matrices.xlsx.
5. Discussion and conclusions. We present methodology to model sparse
graphical models in the presence of class variables in high-dimensional set-
tings, with a particular focus on protein signaling networks. Our methods
allow for borrowing strength between classes to assess differential and com-
mon networks between the classes of cancer/tumor conditions. In addition,
our method allows for the effective use of prior information about signal-
ing pathways that is already available to us from various sources to help
in decoding the complex protein networks. Improved understanding of the
differential networks can be crucial for biologists when designing their ex-
periments, allowing them to concentrate on the most important factors that
distinguish tumor types. Such information may also help to narrow the drug
targets for specific types of cancer. Knowledge of the common networks can
be used to develop a drug for two different types of cancer that targets pro-
teins that are active in both types. Data on the differential edges may be
used as a good screening analysis, allowing researchers to eliminate unimpor-
tant proteins and concentrate on effective proteins when designing advanced
patient-based translational experiments.
In this article we focused on undirected graphical models and not on di-
rected (casual) networks. Directed graphical models, such as Bayesian net-
works and directed acyclic graphs (DAGs), have explicit causal modeling
goals that require further modeling assumptions. In our formulation, we
provide a natural and useful technical step in the identification of high pos-
terior probability undirected graphical models, assuming a random sampling
paradigm. In addition, our models infer network topologies that assume a
steady-state network. Some of the protein networks may be dependent on
causal relations between the nodes, which would require us to model data
over time to infer the complete dynamics of the network. We leave this task
for future consideration.
With regard to computation time, our MCMC chains are fairly fast for
high-dimensional data sets such as those we considered, with a 5000-iteration
run taking about 15 minutes. The source code, in MATLAB (The Math-
works, Inc., Natick, MA), takes advantage of several matrix optimizations
available in that language environment. The computationally-involved step
is the imposition of a positive definiteness on the correlation matrix. Op-
timizations to the code have been made by porting some functions into C.
The software is available by contacting the first author.
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Our main motivation for this work was to provide a constructive frame-
work to conduct classification using sparse graphical methods that incorpo-
rate prior information. We assume parametric structures (likelihood/priors)
throughout for ease of interpretation and computation, and our results in-
dicate that this performs reasonably well on both real and simulated data
sets. Extending to nonparametric settings would be an excellent avenue of
future research that we would wish to undertake.
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SUPPLEMENTARY MATERIAL
Supplement to “Bayesian sparse graphical models for classification with
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ness constraint, Appendix B: Full conditional distributions and Appendix
C: Simulations.
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